These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 32950451)
61. Nuclear tracers for transthyretin cardiac amyloidosis: time to bone up? Ruberg FL; Miller EJ Circ Cardiovasc Imaging; 2013 Mar; 6(2):162-4. PubMed ID: 23512778 [No Abstract] [Full Text] [Related]
62. Echocardiographic tools for prognostic stratification in transthyretin cardiac amyloidosis: a new arrow in the quiver. Citro R; Silverio A; Bellino M Eur Heart J Cardiovasc Imaging; 2024 Mar; 25(4):480-481. PubMed ID: 38279943 [No Abstract] [Full Text] [Related]
64. Kidney involvement in transthyretin cardiac amyloidosis - Role of urinary albumin to creatinine ratio and need for further evidence generation. Khan MS; Sperry BW; Butler J Eur J Heart Fail; 2024 Jan; 26(1):74-76. PubMed ID: 38191996 [No Abstract] [Full Text] [Related]
65. Diagnosis of amyloid neuropathy. Kapoor M; Rossor AM; Jaunmuktane Z; Lunn MPT; Reilly MM Pract Neurol; 2019 Jun; 19(3):250-258. PubMed ID: 30598431 [TBL] [Abstract][Full Text] [Related]
66. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser). Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724 [No Abstract] [Full Text] [Related]
67. Response: Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor. Henein MY; Lindqvist P Amyloid; 2018 Jun; 25(2):136. PubMed ID: 29529882 [No Abstract] [Full Text] [Related]
69. Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg. Watanabe T; Obayashi K; Misumi Y; Tasaki M; Shinriki S; Ando T; Akagami T; Ueda M; Yamashita T; Hirotani S; Ando Y Amyloid; 2017 Mar; 24(sup1):119. PubMed ID: 28434332 [No Abstract] [Full Text] [Related]
70. Different NT-proBNP circulating levels for different types of cardiac amyloidosis. Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991 [TBL] [Abstract][Full Text] [Related]
71. Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. Miller RJH; Fine N J Nucl Cardiol; 2022 Dec; 29(6):3111-3114. PubMed ID: 34921352 [No Abstract] [Full Text] [Related]
72. Spontaneous intramyocardial haemorrhage in a patient with wild-type transthyretin cardiac amyloidosis. Liu C; Witschey WRT; Santangeli P; Han Y Eur Heart J; 2021 Dec; 42(48):4929. PubMed ID: 33346807 [No Abstract] [Full Text] [Related]
73. [Classification of cardiac amyloidosis: an immunohistochemical analysis]. Li L; Duan XJ; Sun Y; Lu Y; Xu HY; Wang QZ; Wang HY Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):105-109. PubMed ID: 29429161 [No Abstract] [Full Text] [Related]